Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
19,605,356
-
Shares change
-
-1,523,026
-
Total reported value, excl. options
-
$146,635,724
-
Value change
-
-$12,713,555
-
Put/Call ratio
-
1.6%
-
Number of buys
-
49
-
Number of sells
-
-37
-
Price
-
$7.48
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2016
112 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2016.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19,605,356 shares
of 236,234,693 outstanding shares and own 8.3% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3,583,061 shares), FIRST MANHATTAN CO (1,864,600 shares), FMR LLC (1,688,855 shares), Nantahala Capital Management, LLC (1,680,390 shares), BlackRock Fund Advisors (1,408,498 shares), VANGUARD GROUP INC (1,085,393 shares), PERCEPTIVE ADVISORS LLC (893,600 shares), BlackRock Institutional Trust Company, N.A. (775,035 shares), venBio Select Advisor LLC (621,873 shares), and ACUTA CAPITAL PARTNERS, LLC (600,000 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.